Featured Image Credit: Supplied/Getty Stock Image
Topics: Ozempic, Mounjaro, Health, World News, News, Life, Astrology, Tyla Exclusive
.jpeg)
Madison Burgess
Topics: Ozempic, Mounjaro, Health, World News, News, Life, Astrology, Tyla Exclusive
A Brazillian seer dubbed the 'Living Nostradamus' has issued a concerning prediction about the rapid rise of weight loss drugs.
Athos Salomé, 38, an alleged psychic and prophet, has alleged to have foreseen dozens of global disasters and events, including the Covid-19 pandemic and Queen Elizabeth II's death.
His eerie success rate when it comes to foreseeing the future has earned him the nickname comparing him to the late French astrologer.
And for those who are still confused, the original Nostradamus, real name Michel de Nostredame, was a famous mystic who died in 1566 and issued almost 1,000 predictions in the form of poems.
Advert
As we're nearing the end of the year, speaking exclusively to Tyla, Salomé has shared a slew of new predictions about what 2026 holds for the world - and some of them concern drugs that aid weight loss.
GLP-1 injectables like Mounjaro, Wegovy and Ozempic have been gaining popularity in recent years as more people are turning to shed the pounds.
It's important to note that Ozempic isn't officially approved for weight loss like Mounjaro and Wegovy, and is instead intended to treat people with Type-2 diabetes.
Advert
It was reported that an estimated 1.5 million people in the UK used weight loss medication in March of this year. Meanwhile, over in the US, nearly 12 percent of Americans have used GLP-1 drugs for weight loss.
And with hordes of celebrities sharing their experiences, the number is only climbing.
But, it hasn't come without a slew of both common and rare side effects, with users reporting gastrointestinal issues like nausea, vomiting, diarrhoea, and constipation, as well as hair loss and even changes to their sex drive.
The growing use of the drugs has led people to question what the future holds for this market - and as we say, Salomé has shared his own prediction.
Advert
He claims his prophecies are based on an ancient spiritual entity known as 'Putsatanachia,' as well as the 'Hidden Kabbalah oracle' - the ancient Jewish tradition of mystical biblical interpretation, paired with analysis of symbolic patterns and power cycles.
And for weight loss drugs, he foresees an increase in 'subclinical pancreatitis' and 'medication fatigue'.
He also believes these drugs will 'assume a strategic role within health systems from 2026 onwards' as 'countries depend on these drugs to contain costs and reduce hospital strain' and they 'understand the impact of this dependency'.
Advert
The oracle said in terms of health, he reports 'signs of subclinical pancreatitis in some batches, requiring new monitoring protocols'.
He said: "Another concern is medication fatigue after two and a half years of continuous semaglutide use. The phenomenon marks the natural limits of the first generation of GLP-1 drugs. Adjustments will be necessary to maintain both efficacy and safety."
Earlier this year, some cases of pancreatitis (the inflammation of the pancreas) were reported to be linked to GLP-1 medicines.
While there is no evidence that the drugs directly caused any pancreatitis deaths, health officials have since been prompted to launch a new study into the side effects following the increased reports.
Advert
The data and evidence are also not strong enough for the MHRA to restrict access because pancreatitis is relatively common.
Speaking of the cultural aspects and ethical pressures, he continued: "The impact goes beyond the physical body. The debate now touches behaviour, sexuality and mental health.
"Governments in different countries are requesting additional information to understand the indirect effects of these medications. Ethical pressure has intensified.
"Central questions revolve around priority-setting, clinical criteria and public spending. I foresees these decisions shaping the entire decade."
Salome also foresees 'the era of Ozempic and Mounjaro’s isolated dominance' as being over' as the sector has 'entered a cycle of continuous innovation'.
He added: "The challenge now is understanding how governments will manage this progress.
"The arrival of Chinese companies in the European market represents a strategic shift. I see Europe seeking to reduce its dependence on Novo Nordisk and Eli Lilly. The decision involves considerations of energy, security and economic autonomy.
"I believe that nations able to reduce healthcare spending will gain geopolitical advantage. Obesity medications are beginning to function as diplomatic tools. The issue has reached the agenda of international blocs."
It's important to note that these are, of course, just predictions, and are not by any means set in stone facts - we'll just have to wait and see if they come true!